The control of cell multiplication and differentiation by tumor-promoting phorbol esters including 12-0-tetradecanoylphorbol-13-acetate (TPA) has been studied with different clones of mouse myeloid leukemic cells, a line of human myeloid leukemic cells, and normal mouse bone marrow myeloblasts. TPA induced normal cell differentiation in one of the mouse leukemic clones and this was mediated by induction of the protein inducer of differentiation to macrophages or granulocytes (MGI) in the cells that then differentiated. Other mouse clones were not induced to differentiate by TPA. In one of these clones, TPA induced cell susceptibility to externally added MGI. This effect was not due to a general induction of susceptibility to all compounds because TPA did not induce susceptibility to lypopolysaccharide or dexamethasone in this clone. In the human leukemic cell line, TPA also induced differentiation with the induction of MGI activity and enhanced susceptibility to added MGI. It is suggested that the clonal differences in induction of MGI activity and increased susceptibility to MGI may be associated with differences in receptors for TPA and the ability of TPA to modify receptors for MGI. Studies with normal bone marrow cells have indicated that TPA stimulated MGI activity and also increased susceptibility of normal myeloblasts to induction of multiplication by MGI. The ability of different phorbol esters to produce these effects on normal myeloblasts and myeloid leukemic cells paralleled their ability to act as tumor promoters. The results indicate that a tumor promoter such as TPA can induce the production of and increase cell susceptibility to a normal regulator of cell multiplication and differentiation. TPA has pleiotropic effects. It is suggested that, by these mechanisms, TPA may thus act as a tumor promoter by increasing cell multiplication in initiated cells, induce differentiation in some cells, or inhibit differentiation in other cells, depending on which molecules are being regulated in the TPA-treated cells.
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Studies of tumor development in animals have led to the isolation of various compounds that can promote the formation of skin tumors after initiation by a carcinogen (1) (2) (3) (4) . Among the most potent of these promoters are plant diterpenes including 12-O-tetradecanoylphorbol-13-acetate (TPA) (3) . Compounds such as TPA could promote tumor development by increasing multiplication of the initiated cells. This could then allow the occurrence and eventual selection of cells with other changes, including specific chromosome changes (5) (6) (7) (8) , that are required for malignancy. Experiments on the in vitro effect of TPA on erythroleukemic cells (9, 10) , myogenesis (11) , neuroblastoma (12) , and the formation of adipose cells (13) have indicated that one way in which this increased multiplication could be obtained is by blocking cell differentiation. However, in contrast to the blocking of cell differentiation by TPA in these cell system-as (9) (10) (11) (12) (13) , it has been found (14) that treatment with TPA actually can induce normal differentiation in some myeloid leukemic cells.
The present studies were undertaken to elucidate the mechanism by which TPA may regulate cell multiplication and differentiation by using different clones of mouse myeloid leukemic cells (5, 6, 14-16), a cultured human myeloid leukemic cell line (HL-60) (17) , and normal mouse bone marrow myeloblasts. The clones of mouse myeloid leukemic cells, which differ in their chromosome constitution (6) (5, (14) (15) (16) . Unlike leukemic cells, normal myeloblasts require MGI for cell multiplication (14) .
MATERIALS AND METHODS
Cells and Sources of MGI. Mouse MGI+D+ clones 9 and 11 and MGI+D-clones 5 and 13 were derived (18) from a spontaneous myeloid leukemia in an SL mouse. MGI+D+ clone 7-M18 and MGI-D-clones 1, 6, and 10 were derived from four independently arising x-ray-induced myeloid leukemias in SJL/J mice (15) . The human myeloid leukemic cell line (HL-60) was from a patient with promyelocytic leukemia (17) . Cells by counting the total number of cells at 1-4 days after seeding.
The use of phorbol esters that differ in their tumor-promoting activity on mouse skin (3) has shown that cell attachment and induction of differentiation parallels tumor-promoting ability (Table 2) . Incubation with TPA and MGI gave an enhancing effect on the induction of differentiation in clones 7-M18 and 6 but not in clones 9, 11, 5, and 13 ( (Table 1) indicates that, in these clones, TPA induced cell susceptibility to added exogenous MGI. The addition of suboptimal concentrations (0.1 ng/ml) of TPA and 10% MGI has indicated that this also seems to apply to the HL-60 cells. The properties were tested at 6 days after seeding in vitro and at 10 days after culture in vivo in diffusion chambers in SL mice.
* Compounds and concentrations tested: TPA, 0.5 ng/ml; Act. D, actinomycin D, 1 ng/ml; Me2SO, dimethyl sulfoxide, 1.5%; Ara C, 1-f-D-arabinofuranosylcytosine (cytosine arabihoside), 5 ng/ml; MGI, 50% in human lymphocyte-conditioned medium. There was no induction of differentiation with dexamethasone (400 ng/ml), lipopolysaccharide (10 ,ug/ml), phytohemagglutinin (0.02 mg/ml), dibutyrl cyclic AMP (1-50 ,ug/ml), epidermal or fibroblast growth factor (1 ,ug/ml), The use of conditioned medium from normal bone marrow cells indicates that this cluster formation was due to the induction of some MGI activity by TPA. However, presumably owing to the small amount of induced MGI, most of these clusters had degenerated at 7 days when the number of macrophage and granulocyte colonies (>50 cells) and clusters (10-40 cells) was generally counted. The addition of TPA together with MGI has shown that TPA can increase the number of macrophage and granulocyte colonies and clusters at 7 days after seeding and that the highest increases were obtained with the lower concentrations of MGI (Fig. 3) . The colonies with TPA were also larger and there was a higher increase in the number of macrophage than of granulocyte colonies (10-fold higher at 0.5% MGI). As with all the mouse leukemic clones that responded to TPA, there was already an effect at 1 ng of TPA per ml and optimal induction at 1 kig/ml. The use of different phorbol esters has shown that this enhancing effect on the activity of MGI paralleled tumor-promoting ability. The activity of MGI was not replaced by epidermal or fibroblast growth factor (0.1-1 ,ug/ml) or dexamethasone (0.4 Atg/ml). Addition of indomethacin at 10-20 pug/ml, f-retinoic acid at 1-30 1ug/ml, or antipain or leupeptin at 1-100 /Ig/ml did not inhibit or enhance the effects of TPA on the normal or leukemic cells. 
DISCUSSION
The present results show that TPA induced normal cell differentiation in one clone of mouse myeloid leukemic cells (MGI+D+ clone 7-M18) by inducing the production of MGI activity and in another clone (MGI-D-clone 1) by inducing cell susceptibility to MGI but not to LPS or dexamethasone. TPA also induced differentiation in the human myeloid leukemic cell line HL-60 with the induction of MGI activity and enhanced susceptibility to added MGI. This indicates that TPA can induce differentiation by two different mechanisms. MGI-D-clone 1 was not previously inducible for differentiation by any of the other compounds tested (15, 22, 23) . Treatment with an appropriate compound or combination of compounds may thus make all MGI-D-leukemia cells susceptible to MGI and this may be of therapeutic value (14) . It can be suggested that the differences in response to TPA may be associated with clonal differences in receptors for TPA and the ability of TPA to modify receptors for MGI. There is also a clonal variation in susceptibility to inhibition (25) and induction (26) of differentiation in mouse erythroleukemic cells, possibly due to the same mechanisms in relation to erythropoietin or another physiological regulator of erythroid differentiation. In the human HL-60 cells, dimethyl sulfoxide (17), actinomycin D, or culture in mice in vivo induced differentiation to granulocytes, whereas incubation with TPA or human MGI induced differentiation to macrophages. As is the case with mouse MGI+D+ leukemic clones (14, 18) , this human MGI+D+ line can thus be induced to differentiate to macrophages and granulocytes. Although there appears to be an interaction between TPA and epidermal growth factor on HeLa cells (27) , epidermal or fibroblast growth factor did not induce differentiation or inhibit or enhance the effect of TPA in any of the myeloid leukemic clones.
The myeloid leukemic cells used are independent of MGI for cell multiplication, whereas normal bone marrow myeloblasts require MGI for cell multiplication (14) . TPA induced Cell Biology: Lotern and Sachs (A, 5162 Cell Biology: Lotem and Sachs some MGI activity in normal bone marrow cells. It also increased cell susceptibility to the induction of multiplication by MGI in these normal myeloblasts without inhibiting differentiation. TPA also increases the susceptibility of normal T lymphocytes (unpublished data) to the normal T-cell inducer of multiplication, TCI (21) . This indicates that TPA can increase cell susceptibility to a normal inducer of cell multiplication in more than one cell type. The effects of TPA on normal mouse myeloblasts can be induced by infection with type C virus from mouse MGI+D+ myeloid leukemic cells (28) . These TPA effects may thus be associated with type C virus induction and the surface budding of this virus may modify the receptors for MGI. However, the results obtained with the human myeloid leukemic cell line, which had no detectable type C virus (29) , suggest that TPA may also show activity without virus production. The effects of TPA on normal and leukemic myeloid cells, unlike the in vivo effects on skin (2, 30), were not inhibited by the protease inhibitors tested.
Treatment of cells in culture with TPA can produce other effects in different cells, including inhibition of cell differentiation (9-13), and increased cell transformation (31, 32) , plasminogen activator (33), prostaglandin (34) , sister chromatid exchange (35) , and Epstein-Barr virus (36) , in addition to type C virus. These pleiotropic effects presumably occur due to the induction by TPA of the appropriate molecular changes. TPA can thus induce in appropriate cells various molecules that could influence growth and differentiation. Induction or increased susceptibility to inducers of cell multiplication can stimulate multiplication of initiated cells in tumor promotion. This multiplication could then permit the occurrence and eventual selection of the other cellular changes that are required for malignancy (5-8, 37, 38) . Sister chromatid exchange (35) , and induction of the appropriate viruses, may also play a role in producing more initiated cells and in furthering promotion. Clonal differences in the response to TPA by either mechanism could also produce differences in tumor-promoting activity in different tissues and genetically different animals.
